15 hours ago
In order to maintain the highest standards of product quality and safety for Spartan Stores, Michael Foods, Minnetonka, MN., a producer of hard-boiled eggs is initiating a voluntary product withdrawal on one lot code of hard-boiled eggs due to a possible contamination of Listeria monocytogenes.
|
18 hours ago
THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone ...
|
21 hours ago
A growing number of countries in the Americas are adopting effective measures to
reduce consumption of tobacco and exposure to secondhand...
|
21 hours ago
4thQtrYearAgoRevenue$11,040,000$10,500,000Net Inco$1,650,000$5,770,000Per Share$0.72$2.46
|
21 hours ago
Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.
|
23 hours ago
A major generic drugmaker has paid Bristol-Myers Squibb Co. and Sanofi SA more than $445 million to end a decade-long patent infringement case over blockbuster blood thinner Plavix, the world's second-best-selling drug.Apotex Corp., Canada's biggest drugmaker, has paid the two brand-name...
|
Feb 8
Higher blood levels of cadmium in females, and higher blood levels of lead in males, delayed pregnancy in couples trying to become pregnant, according to a study by researchers at the National Institutes of Health and other academic research institutions.
|
Feb 8
SAN DIEGO (AP) — Diagnostics company Illumina Inc. again rejected a $5.7 billion offer from Roche AG on Tuesday, saying the Swiss drugmaker's bid was "grossly inadequate."
|
Feb 8
CAMBRIDGE, Mass. (AP) — Move over, coffee and Red Bull. A Harvard professor thinks the next big thing will be people inhaling their caffeine from a lipstick-sized tube. Critics say the novel product is not without its risks.
|
Feb 8
Amgen will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. FDA Oncologic Drugs Advisory Committee (ODAC).
|